{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:26:41Z","timestamp":1787023601596,"version":"build-2736575974"},"reference-count":61,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2023,3,31]]},"DOI":"10.18632\/aging.204611","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:19:21Z","timestamp":1679919561000},"page":"2237-2274","source":"Crossref","is-referenced-by-count":30,"title":["A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease"],"prefix":"10.18632","volume":"15","author":[{"given":"Jun","family":"Chen","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University, First Clinical Medical College, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Shou","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University, First Clinical Medical College, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Zhejiang Provincial People\u2019s Hospital, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","article-title":"Anemia in chronic kidney disease.","volume":"3","author":"Warady","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States.","volume":"29","author":"Levey","year":"2007","journal-title":"JAMA"},{"key":"3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","article-title":"Kidney disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease.","volume":"2","author":"Mcmahon","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD.","volume":"2","author":"Lin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"5","article-title":"Anaemia management in chronic kidney disease: update 2015 NICE guideline 8.","author":"National Clinical Guideline Centre","year":"2019","journal-title":"National Institute for Health and Care Excellence (NICE)"},{"key":"6","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States.","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11255-020-02584-x","article-title":"Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.","volume":"5","author":"Sudchada","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MNH.0000000000000317","article-title":"Anemia management in chronic kidney disease and dialysis: a narrative review.","volume":"2","author":"Tangri","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9","doi-asserted-by":"publisher","first-page":"172532","DOI":"10.1016\/j.ejphar.2019.172532","article-title":"JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-\u03b1 protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.","volume":"85","author":"Nangaku","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.18433\/jpps30919","article-title":"Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney Disease.","volume":"2","author":"Zhou","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.","volume":"4","author":"Macdougall","year":"2017","journal-title":"Am J Nephrol"},{"key":"12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.","volume":"1","author":"Bhandari","year":"2017","journal-title":"BMC Nephrol"},{"key":"13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy.","volume":"1","author":"Haase","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"14","doi-asserted-by":"publisher","first-page":"e0143348","DOI":"10.1371\/journal.pone.0143348","article-title":"Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.","volume":"1","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.xkme.2020.06.008","article-title":"Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era.","volume":"2","author":"Coyne","year":"2020","journal-title":"Kidney Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.","volume":"2","author":"Nangaku","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.","volume":"2","author":"Haase","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: First Approval.","volume":"8","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: First Approval.","volume":"8","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40265-020-01444-3","article-title":"Enarodustat: First Approval.","volume":"8","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.","volume":"6","author":"Wish","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"22","doi-asserted-by":"publisher","first-page":"105020","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.","volume":"15","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.phrs.2020.104747","article-title":"Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.","volume":"15","author":"Rahmani","year":"2020","journal-title":"Pharmacol Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"e0266243","DOI":"10.1371\/journal.pone.0266243","article-title":"The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.","volume":"1","author":"Kunadi","year":"2022","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/bcp.15055","article-title":"Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.","volume":"8","author":"Liu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.","volume":"38","author":"Zuo","year":"2019","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.","volume":"38","author":"Wang","year":"2019","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.","volume":"3","author":"Misumi","year":"2019","journal-title":"Adv Ther"},{"key":"29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.","volume":"3","author":"Li","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"30","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.","volume":"6","author":"Neff","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.","volume":"3","author":"Neff","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"32","doi-asserted-by":"publisher","first-page":"573645","DOI":"10.3389\/fphar.2020.573645","article-title":"Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.","volume":"1","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.","volume":"4","author":"Zhu","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-na\u00efve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.","volume":"2","author":"Reusch","year":"2020","journal-title":"Ther Apher Dial"},{"key":"35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2014.00086","article-title":"Hepcidin antagonists for potential treatments of disorders with hepcidin excess.","volume":"5","author":"Arosio","year":"2014","journal-title":"Front Pharmacol"},{"key":"36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00467-011-1832-y","article-title":"Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.","volume":"2","author":"White","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.","volume":"10","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.","volume":"4","author":"Salusky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2215\/CJN.08161109","article-title":"Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.","volume":"5","author":"Salusky","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.","volume":"4","author":"Cobitz","year":"2017","journal-title":"Am J Nephrol"},{"key":"41","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.","volume":"1","author":"Cobitz","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.","volume":"2","author":"Patel","year":"2019","journal-title":"BMC Nephrol"},{"key":"43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.","volume":"6","author":"Singh","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"44","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.","volume":"2","author":"Cobitz","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.","volume":"1","author":"Cobitz","year":"2019","journal-title":"Clin Kidney J"},{"key":"46","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.","volume":"38","author":"Wi\u0119cek","year":"2021","journal-title":"N Engl J Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.","volume":"3","author":"Reusch","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"48","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.","volume":"3","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.jrn.2021.09.003","article-title":"A Prospective, Self-Controlled Pilot Study of the Efficacy of Roxadustat for Erythropoietin Hyporesponsiveness in Patients Requiring Chronic Ambulatory Peritoneal Dialysis.","volume":"3","author":"Zhang","year":"2022","journal-title":"J Ren Nutr"},{"key":"50","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).","volume":"3","author":"Sulowicz","year":"2021","journal-title":"Adv Ther"},{"key":"51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.","volume":"12","author":"Li","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"52","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.","volume":"3","author":"Yu","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.","volume":"14","author":"Bernhardt","year":"2019","journal-title":"Nephron"},{"key":"54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000499111","article-title":"Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.","volume":"4","author":"Krueger","year":"2019","journal-title":"Am J Nephrol"},{"key":"55","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.","volume":"6","author":"Yamamoto","year":"2021","journal-title":"Kidney Int Rep"},{"key":"56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of Molidustat in the Treatment of Anemia in CKD.","volume":"1","author":"Krueger","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.","volume":"14","author":"Hirakata","year":"2019","journal-title":"Nephron"},{"key":"58","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","article-title":"A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.","volume":"7","author":"Hirakata","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"59","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.","volume":"38","author":"Maroni","year":"2021","journal-title":"N Engl J Med"},{"key":"60","doi-asserted-by":"publisher","first-page":"gfaa060","DOI":"10.1093\/ndt\/gfaa060","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.","author":"Khawaja","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"61","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.","volume":"3","author":"Komatsu","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T13:24:14Z","timestamp":1680787454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,3,31]]}},"alternative-id":["204611","36988549"],"URL":"https:\/\/doi.org\/10.18632\/aging.204611","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}